文献速递认知障碍与谵妄多重用药

美国痴呆与非痴呆老年人多重用药比较

Polypharmacy among older adults with dementia compared with those without dementia in the United States.
PubMed 文献 · J Am Geriatr Soc · 2021-06-08

该横断面分析基于2014-2016年美国门诊医疗调查数据,比较痴呆与非痴呆老年人门诊就诊时的多重用药情况。痴呆患者中位用药8种,非痴呆3种;校正后痴呆患者≥5种和≥10种用药的比值比分别为3.0和2.8,且接受高镇静或抗胆碱能药物的比值比为2.5。

要点

  • 痴呆老年人多重用药(≥5种药物)风险是非痴呆老年人的3倍。
  • 痴呆老年人中位用药8种,显著高于非痴呆老年人的3种。
  • 痴呆老年人接受高镇静或抗胆碱能药物的风险增加2.5倍。

核心结论

  • 在代表性门诊样本中,痴呆老年人多重用药极为常见,涉及广泛药物类别。

研究设计与样本

  • 横断面分析,数据来自2014-2016年全国门诊医疗调查(NAMCS),纳入≥65岁痴呆与非痴呆门诊就诊记录,未加权样本为918次痴呆就诊和26543次非痴呆就诊。

主要发现

  • 痴呆患者中位年龄81岁,平均合并2.8种除痴呆外的共病,63%为女性。
  • 痴呆患者中位用药8种,非痴呆患者3种(p < 0.001)。
  • 校正后痴呆患者≥5种用药的比值比(AOR)为3.0(95% CI: 2.1-4.3),≥10种用药的AOR为2.8(95% CI: 2.0-4.2)。
  • 痴呆患者接受至少一种高镇静或抗胆碱能药物的AOR为2.5(95% CI: 1.6-3.9)。
  • 痴呆患者用药主要来源为心血管和中枢神经系统药物,其他类别用药也普遍高于非痴呆患者。

关键数值与推荐

  • 多重用药定义为处方和/或非处方药物≥5种。
  • 痴呆患者≥5种用药AOR 3.0(95% CI: 2.1-4.3),≥10种用药AOR 2.8(95% CI: 2.0-4.2)。
  • 高镇静或抗胆碱能药物使用AOR 2.5(95% CI: 1.6-3.9)。

临床怎么用

  • 对痴呆老年人应常规审查用药,尤其关注心血管和中枢神经系统药物及高镇静/抗胆碱能药物。
  • 处理痴呆老年人多重用药需跨学科多团队协作。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND/OBJECTIVES: In older persons with dementia (PWD), extensive medication use is often unnecessary, discordant with goals of care, and possibly harmful. The objective of this study was to determine the prevalence and medication constituents of polypharmacy among older PWD attending outpatient visits in the United States. DESIGN: Cross-sectional analysis. SETTING AND PARTICIPANTS: PWD and persons without dementia (PWOD) aged ≥65 years attending outpatient visits recorded in the nationally representative National Ambulatory Medical Care Survey (NAMCS), 2014-2016. MEASUREMENTS: PWD were identified as those with a diagnosis of dementia on the NAMCS encounter form and/or those receiving an anti-dementia medication. Visits with PWD and PWOD were compared in terms of sociodemographic, practice/physician factors, comorbidities, and prescribing outcomes. Regression analyses examined the effect of dementia diagnosis on contributions by clinically relevant medication categories to polypharmacy (defined as being prescribed ≥5 prescription and/or nonprescription medications). RESULTS: The unweighted sample involved 918 visits for PWD and 26,543 visits for PWOD, representing 29.0 and 780 million outpatient visits. PWD had a median age of 81 and on average had 2.8 comorbidities other than dementia; 63% were female. The median number of medications in PWD was eight compared with three in PWOD (p < 0.001). After adjustment, PWD had significantly higher odds of being prescribed ≥5 medications (AOR 3.0; 95% CI: 2.1-4.3) or ≥10 medications (AOR 2.8; 95% CI: 2.0-4.2) compared with PWOD. The largest sources of medications among PWD were cardiovascular and central nervous system medications; usage from other categories was generally elevated in PWD compared with PWOD. PWD had higher odds of receiving at least one highly sedating or anticholinergic medication (AOR 2.5; 95% CI: 1.6-3.9). CONCLUSION: In a representative sample of outpatient visits, polypharmacy was extremely common among PWD, driven by a wide array of medication categories. Addressing polypharmacy in PWD will require cross-cutting and multidisciplinary approaches.

来源:J Am Geriatr Soc,查看原文。版权归原作者所有。

引用

  1. Growdon ME, Gan S, Yaffe K, et al. Polypharmacy among older adults with dementia compared with those without dementia in the United States. J Am Geriatr Soc. 2021. PMID: 34101822. doi:10.1111/jgs.17291

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。